Patents by Inventor Guy Georges

Guy Georges has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HER3 antigen binding proteins binding to the beta-hairpin of HER3
    Patent number: 10626177
    Abstract: The invention relates to anti-HER3 antigen binding proteins, e.g. anti-HER3 antibodies, that bind to the beta-hairpin of HER3, methods for selecting these antigen binding proteins, their preparation and use as medicament.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: April 21, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, David Casagolda Vallribera, Guy Georges, Michael Gerg, Gerhard Niederfellner, Christian Scholz, Michael Schraeml
  • Bispecific HER2 antibodies and methods of use
    Patent number: 10584178
    Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: March 10, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Rebecca Croasdale-Wood, Lydia Jasmin Hanisch, Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Claudio Sustmann, Pablo Umana
  • ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH TAILORED AFFINITY
    Publication number: 20200055931
    Abstract: Herein is reported an anti-transferrin receptor antibody that specifically binds to human transferrin receptor and cynomolgus transferrin receptor, which comprises i) a humanized heavy chain variable domain derived from the heavy chain variable domain of SEQ ID NO: 01, and ii) a humanized light chain variable domain derived from the light chain variable domain of SEQ ID NO: 26, wherein the antibody has an off-rate for the human transferrin receptor that is equal to or less than (i.e. at most) the off-rate of the anti-transferrin receptor antibody 128.1 for the cynomolgus transferrin receptor, whereby the off-rates are determined by surface plasmon resonance, and whereby the anti-transferrin receptor antibody 128.1 has a heavy chain variable domain of SEQ ID NO: 64 and a light chain variable domain of SEQ ID NO: 65.
    Type: Application
    Filed: April 29, 2019
    Publication date: February 20, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Ulrich Goepfert, Jens Niewoehner, Tilman Schlothauer
  • Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
    Patent number: 10561737
    Abstract: Herein is reported a bispecific antibody comprising a first binding specificity that specifically binds to a haptenylated payload and a second binding specificity that specifically binds to a blood brain barrier receptor.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: February 18, 2020
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Ulrich Brinkmann, Guy Georges, Olaf Mundigl, Jens Niewoehner
  • Anti-ANG2 antibodies and methods of use
    Patent number: 10538585
    Abstract: Herein are reported anti-ANG2 antibodies. A specific anti-ANG2 antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 23.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: January 21, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Peter Michael Huelsmann, Hubert Kettenberger, Joerg Moelleken, Michael Molhoj, Joerg Thomas Regula
  • ANTI-BRDU ANTIBODIES AND METHODS OF USE
    Publication number: 20200002437
    Abstract: The invention provides anti-BRDU antibodies and methods of using the same.
    Type: Application
    Filed: March 5, 2019
    Publication date: January 2, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Guy Georges, Johannes Auer, Wilma Lau
  • BISPECIFIC ANTI-HAPTEN/ANTI-BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES, COMPLEXES THEREOF AND THEIR USE AS BLOOD BRAIN BARRIER SHUTTLES
    Publication number: 20200000929
    Abstract: Herein is reported a bispecific antibody comprising a first binding specificity that specifically binds to a haptenylated payload and a second binding specificity that specifically binds to a blood brain barrier receptor.
    Type: Application
    Filed: March 1, 2019
    Publication date: January 2, 2020
    Inventors: Ulrich Brinkmann, Guy Georges, Olaf Mundigl, Jens Niewoehner
  • Covalently linked antigen-antibody conjugates
    Patent number: 10517945
    Abstract: Herein is reported a conjugate comprising an antigen and an antibody that specifically binds to the antigen wherein a covalent bond is formed between the antigen and an amino acid residue in the CDR2 of the antibody, an antibody comprising a cysteine residue at amino acid position 53 (according to Kabat) in the heavy chain CDR2 and uses thereof.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: December 31, 2019
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Joerg Benz, Ulrich Brinkmann, Stefan Dengl, Sebastian Dziadek, Guy Georges, Michael Grote, Alexander Haas, Eike Hoffmann
  • THE CONTORSBODY - A SINGLE CHAIN TARGET BINDER
    Publication number: 20190389971
    Abstract: Herein is reported a circular fusion polypeptide comprising a first part of a binding domain, a second part of a binding domain and a spacer domain, wherein the spacer domain is a polypeptide and comprises at least 25 amino acid residues, the first part of the binding domain is a polypeptide and is fused via a first linker to the N-terminus of the spacer domain, the second part of the binding domain is a polypeptide and is fused via a second linker to the C-terminus of the spacer domain, the first part of the binding domain and the second part of the binding domain are associated with each other and form a binding site that specifically binds to a target.
    Type: Application
    Filed: November 1, 2018
    Publication date: December 26, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Friederike Hesse, Sabine Imhof-Jung, Josef Platzer
  • ANTI-TIM3 ANTIBODIES AND METHODS OF USE
    Publication number: 20190382480
    Abstract: The invention provides anti-TIM3 antibodies and methods of using the same.
    Type: Application
    Filed: February 6, 2019
    Publication date: December 19, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Valeria Lifke, Guy Georges, Victor Levitsky, Oliver Ploettner, Stefan Seeber, Barbara Weiser, Ildiko Wuensche, Adrian Zwick
  • ANTI-PD1 ANTIBODIES AND METHODS OF USE
    Publication number: 20190382489
    Abstract: The present invention relates to anti-PD1 antibodies and methods of using the same.
    Type: Application
    Filed: December 18, 2018
    Publication date: December 19, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: JOERG BENZ, LAURA CODARRI DEAK, STEFAN DENGL, SEBASTIAN FENN, JENS FISCHER, GUY GEORGES, CHRISTIAN KLEIN, VIKTOR LEVITSKI, VALERIA LIFKE, OLIVER PLOETTNER, STEFAN SEEBER, BARBARA WEISER, ILDIKO WUENSCHE, ADRIAN ZWICK
  • Disulfide-linked multivalent MHC class I comprising multi-function proteins
    Patent number: 10501521
    Abstract: Herein is reported a disulfide-linked multivalent multi-function protein, characterized in that it comprises two or more antigen presenting domains, exactly one antibody Fc-region, and at least one antigen binding site, wherein the antigen presenting domain comprises in N- to C-terminal direction either (i) a ?2-microglobulin, and (ii) the extracellular domains ?1, ?2, and ?3 of a class I MHC molecule with a relative frequency of less than 1%, or (i) a T-cell response eliciting peptide, (ii) a ?2-microglobulin, and (iii) the extracellular domains ?1, ?2, and ?3 of a class I MHC molecule with a relative frequency of 1% or more, wherein the antigen binding site binds to a cancer cell surface antigen or a virus-infected cell surface antigen and wherein the antigen presenting domain has at least two non-naturally occurring cysteine residues which form an intrachain/interdomain disulfide bond.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: December 10, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Guy Georges, Sabine Imhof-Jung, Hendrik Knoetgen, Martina Schmittnaegel
  • Humanized anti-Tau(pS422) antibodies and methods of use
    Patent number: 10465000
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: November 5, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Fiona Grueninger, Guy Georges, Olaf Mundigl, Michael Schraeml, Bernd Bohrmann, Ulrich Goepfert, Joerg Benz, Hubert Kettenberger
  • ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF
    Publication number: 20190300614
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: March 25, 2019
    Publication date: October 3, 2019
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Nikolaos DIMOUDIS, Georg FERTIG, Alexander FIDLER, Guy GEORGES, Klaus KALUZA, Martin LANZENDOERFER, Carola RIES, Stefan SEEBER, Marlene THOMAS
  • Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
    Patent number: 10407511
    Abstract: Herein is reported a conjugate comprising a helicar motif amino acid sequence containing compound and an antibody that specifically binds to the helicar motif amino acid sequence characterized by a covalent bond between the helicar motif amino acid sequence containing compound and an amino acid residue in the CDR2 of the anti-helicar antibody, whereby the CDR2 is determined according to Kabat.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: September 10, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Guy Georges, Eike Hoffmann, Georg Tiefenthaler, Ekkehard Moessner, Stefan Dengl, Achim Gaertner
  • Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4
    Patent number: 10364290
    Abstract: The invention relates to anti-HER3/HER4 antigen binding proteins, e.g. anti-HER3/HER4 antibodies, that bind to the beta-hairpin of HER3 and the beta-hairpin of HER4, methods for selecting these antigen binding proteins, their preparation and use as medicament.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: July 30, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, Guy Georges, Michael Gerg, Gerhard Niederfellner, Christian Scholz, Michael Schraeml
  • Anti-IL-1beta antibodies
    Patent number: 10344085
    Abstract: Herein are reported humanized anti-IL-1beta antibodies that are humanized variants of the murine anti-IL-1beta antibody H34. A specific humanized antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 25, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 27, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 28.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: July 9, 2019
    Assignee: Hoffman-La Roche, Inc.
    Inventors: Stefan Dengl, Peter Michael Huelsmann, Christian Gassner, Sebastian Breuer, Olaf Mundigl, Guy Georges, Ralf Schumacher, Guido Hartmann, Sabine Gruener
  • Anti-transferrin receptor antibodies with tailored affinity
    Patent number: 10323089
    Abstract: Herein is reported an anti-transferrin receptor antibody that specifically binds to human transferrin receptor and cynomolgus transferrin receptor, which comprises i) a humanized heavy chain variable domain derived from the heavy chain variable domain of SEQ ID NO: 01, and ii) a humanized light chain variable domain derived from the light chain variable domain of SEQ ID NO: 26, wherein the antibody has an off-rate for the human transferrin receptor that is equal to or less than (i.e. at most) the off-rate of the anti-transferrin receptor antibody 128.1 for the cynomolgus transferrin receptor, whereby the off-rates are determined by surface plasmon resonance, and whereby the anti-transferrin receptor antibody 128.1 has a heavy chain variable domain of SEQ ID NO: 64 and a light chain variable domain of SEQ ID NO: 65.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: June 18, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Ulrich Goepfert, Jens Niewoehner, Tilman Schlothauer
  • Humanized anti-Tau(pS422) antibodies and methods of use
    Patent number: 10308710
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: June 4, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Fiona Grueninger, Guy Georges, Olaf Mundigl, Michael Schraeml, Bernd Bohrmann, Ulrich Goepfert, Joerg Benz, Hubert Kettenberger
  • Antibodies against human CSF-1R and uses thereof
    Patent number: 10287358
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: May 14, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Guy Georges, Klaus Kaluza, Martin Lanzendoerfer, Carola Ries, Stefan Seeber, Marlene Thomas